Parkinson’s disease affects more than ten million people worldwide, and its numbers continue to climb as populations age. Yet the diagnosis remains stubbornly clinical, resting on the observation of motor symptoms such as tremor, rigidity, and slowness of movement. By the time those symptoms become obvious, a substantial fraction of the dopamine-producing neurons in the substantia nigra has already been lost, and no available therapy can restore them. Decades of research have made clear that Parkinson’s begins long before tremors appear, with disturbances in protein handling, mitochondrial function, inflammation, and metabolism unfolding across years or even decades. A reliable molecular readout of that process, drawn from an accessible body fluid, has been a long-standing goal of the field.

The new study addresses that goal through a targeted lens on the urinary metabolome. Rather than attempting to measure every small molecule in urine at once, the researchers focused on amines and phenols, two chemically related classes of compounds that include neurotransmitter breakdown products, microbial metabolites, and products of amino acid metabolism. To capture these molecules comprehensively, they used dansylation chemistry, a labeling technique in which dansyl chloride reacts with compounds bearing an amine or phenol group, attaching a fluorescent and easily ionizable tag to each one. This derivatization dramatically enhances the detectability of these compounds in liquid chromatography–mass spectrometry, boosting sensitivity, improving chromatographic separation, and suppressing interference from salts and other matrix components that normally complicate urine analysis.

The strategy allowed the team to profile thousands of tagged metabolite features in each urine sample with high reproducibility. Urine was collected from patients with Parkinson’s disease and from matched healthy controls, and the dansylated extracts were analyzed under standardized conditions. After rigorous preprocessing to align chromatographic peaks, remove noise, and normalize signal intensities across batches, the resulting data matrix captured the amine and phenol submetabolome of each participant in exquisite detail. Statistical and machine-learning approaches were then applied to identify the metabolite features that best discriminated patients from controls and to build predictive models capable of classifying new samples.

The analysis revealed a coherent disease signature rather than a scattering of random chemical differences. Among the compounds that shifted most consistently were metabolites tied to neurotransmitter metabolism, including products of the catecholamine pathways that are directly affected by the degeneration of dopaminergic circuits. Other discriminating features pointed to alterations in phenolic compounds, many of which originate in the gut, where microbial enzymes transform dietary constituents into phenols that are absorbed into the bloodstream and excreted by the kidneys. The involvement of these gut-derived molecules fits squarely within a growing body of evidence linking the intestinal microbiome to Parkinson’s disease, from changes in microbial composition reported in patient cohorts to the observation that gastrointestinal symptoms often precede motor onset by many years.

Beyond individual metabolites, the investigators examined the pathways in which the altered compounds participate. The results implicate disturbances in the metabolism of tyrosine and phenylalanine, the aromatic amino acids that serve as precursors to dopamine and to numerous phenolic products, as well as in tryptophan catabolism, which feeds both the serotonin and the kynurenine pathways and has been repeatedly connected to neurodegeneration and neuroinflammation. Shifts in these interconnected routes suggest that Parkinson’s disease is accompanied not by a single metabolic lesion but by a coordinated remodeling of how the body processes aromatic compounds, a remodeling that reflects the combined influence of the brain, the periphery, and the resident microbiota.

The translational payoff of the study lies in its biomarker candidates. Using feature-selection algorithms, the researchers distilled the thousands of measured variables down to a compact panel of metabolites that together classify samples with high accuracy in the discovery data and hold up under cross-validation. The panel’s performance was evaluated using standard metrics, including the area under the receiver operating characteristic curve, and the selected markers retained discriminative power when tested on independent sample sets. Enrichment analyses confirmed that the chosen compounds were not statistical artifacts but chemically meaningful indicators, clustering in the same metabolic pathways implicated by the broader dataset. A urine test built on such a panel could be repeated easily, costs little compared with imaging or cerebrospinal fluid analysis, and could in principle be deployed in clinics and community settings far beyond specialized movement disorder centers.

Methodological rigor underpins the credibility of these findings. Dansylated metabolomics is technically demanding, and the authors took extensive precautions to ensure that the observed differences reflected genuine biology rather than analytical drift. Internal standards were used to monitor derivatization efficiency, quality-control samples were interspersed throughout the analytical runs to track instrument stability, and batch effects were corrected statistically before group comparisons were made. Putative metabolite identifications were assigned with appropriate levels of confidence based on accurate mass, retention time, and comparison with labeled standards where available, following the community conventions for reporting metabolomics data. This attention to annotation standards matters, because it allows other laboratories to reproduce the measurements and to build on the reported signatures.

The study also carries implications for how Parkinson’s disease is understood at a systems level. Metabolomics sits at the downstream end of the biological information flow, integrating changes in genes, transcripts, proteins, and environment into a chemical readout of physiology. The urinary amine and phenol submetabolome, in particular, sits at the convergence of central neurotransmitter metabolism, peripheral amino acid handling, and gut microbial activity. Its alteration in Parkinson’s disease reinforces the view of the disorder as a multisystem condition in which the gut-brain axis and peripheral metabolism are active participants rather than bystanders. That perspective is already reshaping therapeutic thinking, with interventions targeting the microbiome, the enteric nervous system, and systemic metabolism joining the traditional focus on neurons of the substantia nigra.

Important caveats remain. The metabolic signature reported here was established in specific cohorts, and its generalizability across populations, disease stages, medications, diets, and comorbidities will need confirmation in large, prospective, multicenter studies. Levodopa therapy, which virtually all patients eventually receive, is itself a rich source of dopamine metabolites and must be carefully accounted for in any diagnostic application. Longitudinal data will be essential to determine whether the biomarker panel tracks disease progression, predicts conversion from prodromal states such as REM sleep behavior disorder, or responds to disease-modifying treatments once such treatments become available. Standardization of sample collection, storage, and processing across sites will likewise be critical before a urine-based test can enter routine practice.

Even so, the study represents a substantial step toward a long-elusive goal. It demonstrates that a chemically defined slice of the urinary metabolome, accessed through a well-established derivatization technique and interrogated with modern mass spectrometry and machine learning, carries enough disease-specific information to distinguish Parkinson’s patients from healthy controls with confidence. If validated at scale, the approach could complement emerging tools such as alpha-synuclein seed amplification assays and advanced imaging, offering a complementary, low-cost, and patient-friendly measure of the disease’s systemic chemistry. In a condition whose diagnosis currently depends on the arrival of irreversible motor damage, a simple urine test that reflects the underlying biology earlier would be a genuinely transformative addition to the clinical arsenal, and the present work provides a detailed molecular roadmap for building one.

Subject of Research: Urinary amine and phenol submetabolome profiling for Parkinson's disease biomarker discovery

Article Title: Decoding the metabolic landscape of Parkinson’s disease: dansylated urinary amines and phenols submetabolomes for signature profiling and biomarker discovery

Article References: Li, Z., Cui, P., Zhang, L., Huang, X., Zhou, Y., Xu, S., Mao, Y., Wang, Y., Liu, L., & Zhang, Y. (2026). Decoding the metabolic landscape of Parkinson’s disease: dansylated urinary amines and phenols submetabolomes for signature profiling and biomarker discovery. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01572-9

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01572-9

Keywords: Parkinson's disease, metabolomics, urinary biomarkers, dansylation, mass spectrometry, biomarker discovery, gut microbiome, neurodegeneration, dopamine metabolism, gut-brain axis, Decoding, metabolic

T cell exhaustion was first characterized in the context of chronic viral infections, where researchers observed that T cells exposed to persistent antigen stimulation lost their ability to produce key inflammatory molecules such as interleukin-2 and tumour necrosis factor. Over time, these cells also lost cytotoxic function, the very machinery they use to kill infected or malignant cells. Cancer, particularly solid tumours, creates a similar situation of chronic antigen exposure. Tumour cells continuously present mutated or overexpressed proteins that T cells can recognize, but instead of a swift, decisive attack, the interaction stretches into months or years. This perpetual stimulation, combined with a suppressive tissue environment, drives T cells into increasingly dysfunctional states.

The tumour microenvironment amplifies this process through multiple converging pressures. Solid tumours are frequently hypoxic, meaning oxygen levels are low, which restricts the metabolic activity T cells require to sustain an energetic response. Nutrient competition is fierce, as rapidly dividing cancer cells consume glucose and amino acids such as glutamine, leaving T cells starved of fuel. Lactic acid secreted by tumours acidifies the surroundings and further impairs immune metabolism. On top of these metabolic constraints, tumour cells and associated stromal cells release immunosuppressive signalling molecules, including transforming growth factor beta and prostaglandins, while recruiting regulatory T cells and myeloid-derived suppressor cells that actively dampen immune attack. Each of these forces contributes to the progressive erosion of T cell function.

A crucial insight from recent research is that exhaustion is not a single uniform state but a spectrum of differentiation. Studies using single-cell RNA sequencing and T cell receptor tracking have revealed that exhausted populations contain both progenitor-like cells and terminally exhausted cells. Progenitor exhausted T cells retain a limited capacity to proliferate and can persist over time, serving as a reservoir from which other exhausted cells arise. Terminal exhausted cells, by contrast, are locked into a dysfunctional program marked by the loss of proliferative potential and reduced effector cytokine production. This distinction matters enormously for therapy, because checkpoint blockade immunotherapies appear to depend heavily on reinvigorating the progenitor compartment rather than resurrecting the terminal cells directly.

Central to the molecular identity of exhausted T cells is the transcription factor TOX, which becomes highly expressed as exhaustion deepens. TOX does not act alone; it works within broader gene regulatory networks that reshape the cell’s identity. Exhausted T cells express inhibitory receptors such as PD-1, TIM-3, LAG-3 and TIGIT on their surface, which serve as markers of the exhausted state and, in some cases, actively transmit suppressive signals. They also shift their metabolic profile, relying more heavily on fatty acid oxidation and oxidative phosphorylation rather than the glycolytic metabolism that characterizes robustly activated T cells. These changes are not merely consequences of a hostile environment; they reflect a fundamental reprogramming of cellular identity.

That reprogramming is epigenetic in nature, and this is one of the most consequential findings in the field. Exhausted T cells accumulate stable chromatin modifications that lock in their dysfunctional gene expression patterns. Enhancer regions that once supported the expression of effector molecules are remodelled and silenced, while new regulatory elements are opened to sustain inhibitory receptor expression. The result is a state that resists simple reversal. Even when the source of chronic antigen stimulation is removed, exhausted T cells often fail to return to their original functional program, because the epigenetic landscape that governed it has been irreversibly altered. This epigenetic rigidity helps explain why some patients respond spectacularly to immune checkpoint inhibitors while others derive little benefit.

Immune checkpoint blockade, exemplified by antibodies against PD-1 and CTLA-4, has transformed the treatment of melanoma, lung cancer, kidney cancer and several other malignancies. These therapies work in part by interrupting the inhibitory signals that exhaust T cells receive. Yet the overall response rates across cancer types remain far from universal, and the review underscores that the depth of exhaustion within a patient’s tumour infiltrating lymphocytes is a major determinant of success. Tumours with abundant progenitor exhausted T cells that still retain proliferative capacity tend to respond better, whereas tumours dominated by terminal exhaustion or lacking T cell infiltration altogether, sometimes described as cold tumours, respond poorly. This understanding has fuelled efforts to combine checkpoint inhibitors with other interventions that can broaden and deepen immune responses.

Among the most promising strategies is the combination of checkpoint blockade with therapies that reshape the tumour microenvironment itself. Agents that block transforming growth factor beta signalling, deplete regulatory T cells, or reprogramme myeloid suppressor cells may relieve some of the pressures driving exhaustion in the first place. Metabolic interventions, such as drugs that improve oxygen delivery or alter nutrient availability, represent another frontier. Oncolytic viruses and radiation therapy can convert cold tumours into inflamed ones by releasing tumour antigens and provoking innate immune activation, drawing fresh waves of T cells into the tumour that have not yet undergone exhaustion. Adoptive cell therapies, including chimeric antigen receptor T cells and tumour infiltrating lymphocyte therapy, introduce freshly armed immune cells but face the same risk of becoming exhausted once they encounter the suppressive tumour milieu, prompting efforts to engineer them with enhanced fitness and resistance to suppression.

Looking ahead, the review highlights the potential of manipulating the epigenetic and transcriptional programs that define exhaustion. Drugs targeting DNA methylation and histone modification are already approved for certain cancers, and researchers are investigating whether such agents can loosen the epigenetic locks that keep exhausted T cells dysfunctional. More precise approaches may one day selectively reprogramme the enhancer landscape of exhausted T cells, restoring effector function while preserving the cells’ tumour specificity. Single-cell and spatial profiling technologies continue to refine the map of exhaustion states within tumours, enabling clinicians to stratify patients according to the immunological character of their disease and to monitor how therapies shift T cell states over time.

Decoding T cell exhaustion in the tumour microenvironment is ultimately about recovering a lost weapon. The immune system already possesses cells capable of eliminating cancer; the challenge is that tumours have learned to wear them down through chronic stimulation and environmental hostility. By dissecting the transcriptional, epigenetic and metabolic architecture of exhaustion, researchers are converting what once seemed like an irreversible defeat into a set of addressable molecular mechanisms. Each layer of understanding brings the field closer to combination therapies that can prevent exhaustion, reverse it in its earlier stages, or work around it when it has become entrenched, offering new hope for patients whose cancers have so far resisted the immune system’s grasp.

Subject of Research: T cell exhaustion in the tumour microenvironment and its implications for cancer immunotherapy

Article Title: Decoding T cell exhaustion in the tumour microenvironment

Article References: Park, J. A., Im, J., & Hwang, S.-M. (2026). Decoding T cell exhaustion in the tumour microenvironment. Experimental & Molecular Medicine, 58(8), 2590-2602. https://doi.org/10.1038/s12276-026-01809-w

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01809-w

Keywords: T cell exhaustion, tumour microenvironment, immunotherapy, PD-1, checkpoint blockade, TOX, epigenetics, cancer, inhibitory receptors, single-cell sequencing, Decoding, cell